Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030

"Targeted Alpha Therapy Emerges as a Breakthrough in Precision Oncology, Offering Superior Efficacy Over Beta-Emitters and Advancing Treatment for Resistant Cancers"

Boston, Oct. 17, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Targeted Alpha Therapies for Cancer Treatment: Global Market” was valued at $199.6 million in 2024, and is expected to grow at a CAGR of 44% during the period 2025 to 2030, reaching a value of $1.1 billion.

The report reviews the global market for targeted alpha therapies (TAT) in cancer treatment. It examines key market trends, revenue data, and segmentation by cancer type. It also explores industry challenges, emerging technologies, and corporate ESG initatives.

Additionally, the report provides insights into the competitive landscape, including pipeline analysis and company profiles with financials, product portfolios, and recent developments. Overall, it serves as a valuable resource for understanding the current dynamics and outlook of the TAT market.

The factors driving the market’s growth include:

Rising Prevalence of Cancer: The global increase in cancer cases, driven by increasingly aging populations and lifestyle factors, is creating demand for more effective and targeted treatments like TAT, which can address cancers that are difficult to treat with conventional methods.

Demand for Precision Medicines: TAT aligns with the growing trend of precision medicine by delivering radiation directly to cancer cells with minimal damage to healthy tissue, making it ideal for personalized treatment strategies.

Unmet Treatment Need in Oncology: Many cancers still lack effective treatment options, especially in advanced stages. TAT offers a promising solution by providing high efficacy with fewer side effects, addressing critical gaps in current oncology care.

Increasing Strategic Initiatives: Pharmaceutical companies, governments, and research institutions are investing in TAT through partnerships, clinical trials, and regulatory support, accelerating its development and market growth.

New Targets and Combination Therapies: Ongoing research is expanding the use of TAT to new cancer types and exploring its combination with other therapies, enhancing its effectiveness and broadening its clinical applications.

Request a sample copy of the global market for targeted alpha therapies for cancer report.

Report Synopsis

Interesting fact:

• Until now there has been only one approved product in the market and even that drug did not attain blockbuster status, even though Bayer had the first mover advantage in the market.

• It is only recently that established players have started focusing on the development of targeted alpha therapies for precision oncology and have entered the market through strategic initiatives such as licensing, collaboration, and acquisitions.

• The pipeline analysis indicated the likelihood of approval and launch of two TAT products by the end of the forecast period. Of these two drugs, RYZ101 will receive approval for neuroendocrine tumors and FPI-2265 will receive approval for prostate cancer. Notably, beta emitting therapies available in the market from Novartis are approved for these indications only.

Emerging startups:

• Ariceum Therapeutics GmbH
• ARTBIO Inc.
• Cellectar Biosciences
• Modulation Therapeutics

The report addresses the following questions:

1. What are the projected size and growth rate of the market?

• The global market for targeted alpha therapies for cancer treatment was valued at $199.6 million in 2024, and it is expected to grow at a CAGR of 44% during the period of 2025 to 2030, reaching a value of $1.1 billion.

2. What are the factors driving the growth of the market?

• The global market’s growth is due to the increasing prevalence of cancer, unmet treatment needs for oncology, growing demand for precision medicine, and limitations associated with beta therapies.

3. What are the restraints/challenges affecting the growth of the market?

• The global market for targeted alpha therapies for cancer is restrained by factors such as manufacturing and supply chain issues associated with isotopes, dosimetry calculations, recoil effect, and regulatory hurdles.

4. What are the opportunities affecting the growth of the market?

• The global market opportunities for growth include ongoing research for new targets and combination therapies.

5. Which market segments are covered in the report?

• The global market for targeted alpha therapies for cancer is segmented by cancer type.

6. Which cancer type will be dominant through 2030?

• The prostate cancer segment will be dominant through 2030.

7. Which region has the largest market share?

• North America holds the largest share of the market and will continue to do so for the foreseeable future. Currently the market is not segmented based on region, as only one product is available, with sales less than $300 million.

Market leaders include:

• ACTINIUM PHARMACEUTICALS INC.
• ADVANCELL PTY LTD.
• BAYER AG
• CONVERGENT THERAPEUTICS INC.
• FUSION PHARM
• NOVARTIS AG
• ORANO MED
• PERSPECTIVE THERAPEUTICS
• RADIOMEDIX INC.
• RAYZEBIO INC.

Related reports:

Radiopharmaceuticals: Technologies and Global Markets: This report offers a detailed overview of the global radiopharmaceuticals market. It covers market segmentation by product, application, production method, and region, while examining key drivers, challenges, and opportunities. The report also highlights competitive dynamics, emerging trends, and recent developments such as emerging technologies, acquisitions, and collaborations.

Purchase a copy of the report direct from BCC Research.

For further information on any of these reports or to make a purchase, contact info@bccresearch.com.    

About BCC Research

BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

BCC Research

Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, U.S.
Email: info@bccresearch.com
Phone: +1 781-489-7301

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.